Targanta's Oritavancin Gets "Complete Response": Another Phase III Needed

FDA threw Targanta a curveball in issuing a "complete response" letter Dec. 8, requiring an additional Phase III study for its complicated skin and skin structure infection treatment oritavancin before approval